Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENGN 
enGene Holdings Inc. Common Stock (ENGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ENGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $21.4
1 Year Target Price $21.4
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.33% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 184.49M USD | Price to earnings Ratio - | 1Y Target Price 21.4 |
Price to earnings Ratio - | 1Y Target Price 21.4 | ||
Volume (30-day avg) 10 | Beta -0.41 | 52 Weeks Range 2.75 - 11.00 | Updated Date 08/15/2025 |
52 Weeks Range 2.75 - 11.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -33.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7542225 | Price to Sales(TTM) - |
Enterprise Value -7542225 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 51105200 | Shares Floating 25590418 |
Shares Outstanding 51105200 | Shares Floating 25590418 | ||
Percent Insiders 13.63 | Percent Institutions 78.23 |
Upturn AI SWOT
enGene Holdings Inc. Common Stock
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing gene therapies for local administration to diseased tissues or organs. The company was founded in 2003 and is headquartered in Montreal, Canada. Its initial focus was on bladder cancer.
Core Business Areas
- Oncolytic Immunotherapy: Development of gene therapies that combine oncolytic virotherapy with immune stimulation for cancer treatment.
- ePD-L1 Platform: Utilizing a non-viral delivery system to deliver genes directly to target cells, focusing on the ePD-L1 product for bladder cancer.
Leadership and Structure
The leadership team includes experienced biotechnology executives. The company operates with a research and development focus, collaborating with academic institutions and clinical sites.
Top Products and Market Share
Key Offerings
- EG-70: An investigational DNA medicine immunotherapy being developed for patients with high-risk, non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guu00e9rin (BCG). Market share is currently 0% as it is not yet approved. Key competitors include Merck (Keytruda), CG Oncology (Cretostimogene grenadenorepvec).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing success in clinical trials. There's high competition and regulatory scrutiny.
Positioning
enGene is positioned as a specialized player in the gene therapy space, focusing on local administration for specific diseases such as bladder cancer. Their ePD-L1 platform aims to improve treatment efficacy and reduce systemic toxicity.
Total Addressable Market (TAM)
The TAM for bladder cancer therapeutics is estimated to be in the billions of dollars annually. enGene is positioned to capture a portion of this market with EG-70 if it achieves regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel ePD-L1 platform
- Focus on local administration, reducing systemic toxicity
- Potential to address unmet needs in bladder cancer treatment
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical trial outcomes
- Competition from established pharmaceutical companies
- Limited financial resources
Opportunities
- Expansion of ePD-L1 platform to other cancer types
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Increasing demand for gene therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- Development of alternative therapies
Competitors and Market Share
Key Competitors
- MRK
- CGON
Competitive Landscape
enGene faces significant competition from established pharmaceutical companies with broader portfolios and more resources. enGene's advantage lies in its novel ePD-L1 platform and focus on local administration.
Growth Trajectory and Initiatives
Historical Growth: enGene's growth has been primarily focused on advancing its clinical programs. Historical revenue is minimal.
Future Projections: Future growth depends on the successful development and commercialization of EG-70 and other pipeline candidates. Analyst estimates vary widely due to the inherent risks in biotech development.
Recent Initiatives: Recent initiatives include ongoing clinical trials for EG-70 and exploring potential applications of the ePD-L1 platform in other disease areas.
Summary
enGene Holdings Inc. is a clinical-stage biotech firm with potential in gene therapies. Its ePD-L1 platform shows promise, but success hinges on clinical trial outcomes. They face stiff competition and financial constraints, demanding strategic partnerships and approvals. While innovative, it's a high-risk, high-reward scenario with considerable uncertainty.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.